United Therapeutics is developing a gene therapy product called Aurora-GT (endothelial nitric oxide-synthase-enhanced endothelial progenitor cells), which is intended to rebuild blood vessels in the lung. Administering this gene therapy involves isolating a PAH patient's autologous endothelial progenitor cells, transfecting the cells with the gene for human endothelial NO-synthase, prior to their ex-vivo expansion, and reintroducing them into the same patient.
United Therapeutics is aiming to diversify its pulmonary hypertension (PH) portfolio with a pipeline gene therapy product, Aurora-GT (endothelial nitric oxide-synthase-enhanced endothelial progenitor cells). The company stands out as the only one with a late-phase gene therapy in development. If successful, this therapy could address critical unmet need in the PH market for options beyond symptomatic treatment. The author awaits further developments for Aurora-GT, as Phase II/III clinical trial data are yet to be released.
Key Topics Covered:
- Drug Overview
- Product Profiles
- Aurora-GT : Pulmonary hypertension
LIST OF FIGURES
Figure 1: Aurora-GT for pulmonary hypertension - SWOT analysis
LIST OF TABLES
Table 1: Aurora-GT drug profile
Table 2: Aurora-GT Phase II trial in pulmonary hypertension
For more information about this report visit https://www.researchandmarkets.com/r/ywlale